Objectives: To develop a pharmacokinetic model describing total and unbound teicoplanin concentrations in patients with haematological malignancy and to perform Monte Carlo simulations to evaluate target attainment of unbound trough concentrations with various dose regimens.
Introduction
Patients with haematological malignancy are particularly susceptible to infections caused by methicillin-resistant Gram-positive pathogens, 1 and teicoplanin is widely used for their treatment. 2, 3 These patients often present with different underlying pathophysiology that can distort the pharmacokinetics (PK) of teicoplanin. 4 Therefore, standard dosing regimens may not consistently result in achievement of therapeutic concentrations.
Importantly, teicoplanin is highly bound to serum albumin ($90%-95%), which can significantly affect the PK of drugs, such as teicoplanin, which are primarily cleared by renal filtration. 5 This might be particularly relevant in patients with haematological malignancy where low serum albumin concentrations are common. 6 Previous studies have demonstrated that serum albumin concentrations are an important determinant of teicoplanin PK variability, with lower albumin concentrations associated with higher unbound (free) fractions (FFs). [7] [8] [9] As unbound drug concentrations are responsible for antimicrobial activity, one could theoretically expect higher active concentrations of teicoplanin in these patients. 8 However, an increased FF may result in increased distribution and CL of drug, which can lead to reduced total concentrations. 10 The situation is further complicated because renal impairment often accompanies hypoalbuminaemia, such as that commonly observed in the critically ill. 11 As CL of unbound teicoplanin occurs almost completely by glomerular filtration, 12 total body CL will decrease with increased renal impairment and will increase with decreases in protein binding. 13 Consequently, unbound pharmacologically active teicoplanin concentrations are difficult to predict in patients with haematological malignancy, with consequences for efficacy and toxicity.
Efficacy of teicoplanin is thought to relate to the ratio of the AUC to the MIC (AUC/MIC). 14 However, in the clinical setting, it is difficult to obtain multiple serum concentrations to determine the AUC and subsequently calculate the AUC/MIC. Therefore, serum trough concentrations, which have been shown to be an appropriate surrogate marker for AUC, 15, 16 are used. At present, total trough concentrations are used to guide dosing, with a suggested therapeutic range between 20 and 60 mg/L. 17 In a previous retrospective study, it was found that a total trough concentration of at least 20 mg/L was associated with improved outcomes for CoNS central line-associated bloodstream infections-the most common infections in patients with haematological malignancy. 1, 9, 18 Currently there is no validated therapeutic range for unbound trough teicoplanin concentrations. However, given 90%-95% protein binding in patients with normal serum albumin concentrations, 5, 19 equivalent lower and upper therapeutic targets for unbound trough concentrations may be estimated as 1-2 mg/L (or 1.5 mg/L) and 3-6 mg/L (or 4.5 mg/L), respectively.
Most studies to date have focussed on total teicoplanin PK without regard for protein binding or unbound concentrations. Further, dosing regimens for teicoplanin have been based on reaching total trough concentration targets that may not be appropriate in patients with altered serum albumin concentrations. There are very few data on dosage regimens to achieve appropriate unbound teicoplanin concentrations in the presence of altered serum albumin concentrations.
The objectives of this study were to develop a population PK model describing unbound and total teicoplanin concentrations and to use Monte Carlo simulations to propose dosing regimens likely to achieve optimal unbound concentrations in patients with haematological malignancy.
Patients and methods

Setting
This single-centre, prospective study was conducted at Tallaght Hospital, Dublin, Ireland from March 2014 to September 2015. Ethical approval was obtained from the Tallaght Hospital/St James's Hospital Joint Research Ethics Committee (REC reference 2013/12/01). The study protocol was approved by the Health Products Regulatory Authority (Clinical Trial Number CT 900/545/1) and the trial was registered with the European Clinical Trials Database Registry (EudraCT number 2013-004535-72). The study was conducted following the guidelines of the Declaration of Helsinki. Written informed consent was obtained from all patients. The inclusion and exclusion criteria for this clinical trial have been described previously.
9,16
Dosing regimen
Teicoplanin (Targocid V R , Sanofi, Dublin, Ireland) was administered intravenously by bolus injection or infusion over 1-5 min. The hospital dosage regimen was 600 mg (or 800 mg if weight .80 kg) q12h for three doses followed by 600 mg (or 800 mg if weight .80 kg) once daily. However, prescribed dosing regimens were at the discretion of treating physicians and the hospital dosage regimen was not always followed.
Blood sampling, handling, storage and measurement Details of blood sampling, handling, storage and measurement have been described previously. 9, 16 In brief, nine blood samples were collected over one dosing interval on day 3 plus single trough samples on days 7 and 10, and 24 and 48 h post-last-dose, when possible. Total and unbound teicoplanin concentrations were determined using a validated HPLC method as described by Roberts et al. 8 
Additional data collection
Additional clinical and demographic data were collected, including fluid balance on day 3. Urine was collected for 24 h on day 3 and CL CR determined. Full details of the additional clinical and demographic data collected have been described previously. 9, 16 PK modelling Two-and three-compartment, simple and complex binding models were fitted to total and unbound teicoplanin concentrations simultaneously with the non-parametric adaptive grid algorithm within the Pmetrics package for R (Los Angeles, CA, USA). 20 Elimination from the central compartment and intercompartmental distribution were modelled as first-order processes.
For the simple binding models, unbound teicoplanin concentrations were related to total teicoplanin concentrations as follows:
where C free is the unbound teicoplanin concentration in mg/L, C total is the total teicoplanin concentration in mg/L, the variable FF is the unbound (free) fraction of teicoplanin, albumin is the serum albumin concentration in g/L and 29 is the median serum albumin concentration in the study cohort in g/L.
For the complex binding models, unbound teicoplanin concentrations were related to total teicoplanin concentrations, assuming albumin is the sole binding protein for teicoplanin in the plasma, as follows:
where B max is the maximum binding concentration of teicoplanin in mg/L, N is the number of teicoplanin binding sites per molecule of albumin, 1880 and 66500 are the molecular weights in g for teicoplanin and albumin, respectively, K D is the equilibrium dissociation constant in mg/L for teicoplanin binding to albumin, K A is the equilibrium association constant in L/mg, k off is the first-order dissociation rate constant in h #1 and k on is the secondorder association rate constant in L/mg/h. For PK modelling purposes, 1.23 binding sites per molecule of albumin, the reported value for the major component of the teicoplanin complex (A2-2), was used. 5, 22 Demographic and clinical characteristics that were considered biologically plausible for affecting teicoplanin PK were tested for inclusion as covariates. These included CL CR , total body weight (TBW), ideal body weight, BMI, fluid balance, serum albumin concentration and age. Individual Bayesian estimates for CL and volume of the central compartment (V c ) obtained from the selected structural model were first plotted against covariate values to assess relationships. If a relationship between the covariate and the PK parameter was observed, then the covariate was tested for inclusion in the population model. If inclusion of the covariate resulted in a statistically significant improvement in the log-likelihood value (P , 0.05) and/or improved the goodness-of-fit plots, it was supported for inclusion in the final model. 23 For initial comparisons, models were run to 100 cycles specifying an ordinary differential equation solver of #1. The final model was run to convergence. A multiplicative error model was supported in this analysis. 95% CIs around median parameter estimates were computed to evaluate parameter precision.
Model diagnostics
The model goodness-of-fit was evaluated by visual inspection of the observed-predicted scatterplots, the coefficient of determination (R 2 ) of the linear regression of the observed-predicted values, and the slopes and intercepts of the regression. 23, 24 Statistical comparisons between nested models with additional covariates were made using the log-likelihood ratio test, where twice the log-likelihood difference (LLD) was evaluated against a v 2 distribution with the appropriate number of degrees of freedom (df).
A model was considered superior if the LLD, based on the df, was statistically significant (P , 0.05). 24 Predictive performance evaluation was based on mean weighted error of predictions minus observations (bias) and biasadjusted mean weighted squared error of predictions minus observations (imprecision) of the population and individual prediction models.
23,24
Probability of target attainment (PTA)
Monte Carlo simulations (n " 1000) were performed using the final covariate model in Pmetrics to determine the PTA for various loading dose regimens for a typical haematological malignancy patient, with a TBW of 70 kg, a CL CR of 70 mL/min and a serum albumin concentration of 29 g/L. Six levels of CL CR (20, 40, 70 , 100, 130 and 160 mL/min) and six levels of serum albumin concentration (15, 20, 25, 30, 35 and 40 g/L), which reflected the distribution of values in the study cohort, were also tested. The PTA for achieving a target trough unbound concentration at 72 h of !1.5 mg/L, and a target trough total concentration at 72 h of !20 mg/L, were calculated. These targets were based on those suggested from previously published studies, assuming 92.5% protein binding for the unbound concentration target. 4, 9, 16, 18 Maintenance doses, for various levels of CL CR , were also simulated. The PTA for achieving a target unbound trough concentration on day 7 (168 h) of !1.5 mg/L was calculated. The PTA (risk) of achieving a trough unbound concentration on day 7 of !4.5 mg/L was also calculated, based on the suggested upper limit for teicoplanin trough total concentrations of 60 mg/L, 17 assuming 92.5% protein binding.
Estimation of unbound teicoplanin concentration from observed total concentration
The kinetic binding model used in this analysis was reduced to an equilibrium binding model using the geometric mean of the dissociation constants (K D " 78.03 mg/L or 41.5 lM teicoplanin concentration), calculated from the mean individual Bayesian estimates for k off and k on . The unbound teicoplanin concentration was then calculated from the observed total teicoplanin concentration and the observed serum albumin concentration using the following equation:
where all concentrations are in lM, and B max 0 is the total concentration of binding sites, assuming 1.23 binding sites per molecule of albumin. 5 
Statistical analyses
All statistical analyses were conducted using IBM SPSS Statistics for Windows v. 22 (IBM Corp., Armonk, NY, USA) or Minitab 16 Statistical Software (Minitab Ltd, Coventry, UK). Data were described as the mean + SD or the median (IQR) for continuous variables and as the number (%) for categorical variables, as appropriate. Statistical significance was defined as P , 0.05.
Results
Thirty patients were recruited into the study PP. The demographic and clinical characteristics of included patients have been previously described in detail. 9, 16 A summary of patient characteristics is provided in Table 1 . Overall, the cohort was of older age, with mild renal impairment, low serum albumin concentrations and severe neutropenia. In total, 352 total and 352 unbound concentrations were analysed.
PK model building
The three-compartment simple binding model improved the fit of the data compared with the two-compartment simple binding model, with a significant reduction in the log-likelihood value [LLD " 762, v Table S1 . The population PK parameter estimates from the final covariate model are provided in Table 2 . The diagnostic plots to confirm the goodness-of-fit of this model are shown in Figure 1 . Visual predictive checks of this final model are shown in Figure S3 .
Dosing simulations
The final covariate model was used for Monte Carlo simulations and the PTA for achieving targeted teicoplanin exposures (trough unbound concentration !1.5 mg/L and trough total concentration !20 mg/L). These simulations showed that using higher loading doses and increasing the number of loading doses administered resulted in an increased PTA for both unbound and total teicoplanin trough concentrations at 72 h. The results for the various teicoplanin loading dose regimen simulations for trough unbound concentrations at 72 h are shown in Figure 2 . The effects of CL CR and serum albumin concentration on the PTA for unbound and total trough concentrations are shown in Figure 3 . These simulations showed that higher CL CR was associated with a reduced PTA for unbound and total trough concentrations at 72 h and that lower serum albumin concentration does not affect the PTA for unbound trough concentrations but reduces the PTA for total trough concentrations at 72 h. Loading dose regimens, stratified by CL CR and serum albumin concentration, associated with a probability of !80% and !90% for achieving target unbound and total trough concentrations at 72 h, are provided in Table 3 . A summary of dosing regimens (loading and maintenance doses), stratified by renal function, associated with a probability of !80% and !90% for achieving a target unbound trough concentration of !1.5 mg/L at 72 h and on day 7, together with the probability (risk) of attaining an unbound trough concentration !4.5 mg/L on day 7, is provided in Table 4 .
Estimation of unbound teicoplanin concentration from observed total concentration
As shown in Figure S4 , the equilibrium binding equation estimated unbound teicoplanin concentrations from measured total concentrations with minimal bias and an acceptable error, consistent with a previously published study. 7 Using this equation, the measured unbound concentration will lie within 50% of the predicted concentration in 97% of cases and within 30% in 75% of cases. A table for estimating the unbound teicoplanin concentration from measured total concentration and serum albumin concentration is provided in Table 5 . The estimated FF at different total teicoplanin concentrations and serum albumin concentrations is provided in Table S2 . This shows that the FF increases with higher total teicoplanin concentrations and lower serum albumin concentrations.
Discussion
To the best of our knowledge, this study is the first to model and simulate total and unbound teicoplanin concentrations simultaneously in patients with haematological malignancy. Using Monte Carlo simulations it was possible to determine dosing regimens Byrne et al. Table 3 . Loading dose regimens, stratified by CL CR and serum albumin concentration, to achieve (i) unbound and (ii) total trough concentration targets at 72 h, with a probability of !80% (!90%) (12) 10 (12) 10 (12) 10 (12) 10 (12) 10 (12) 40 10 (12) 10 (12) 10 (12) 10 (12) 10 (12) 10 (12) 70 12 (15) 12 (15) 12 (15) 12 (15) 12 (15) 12 (15) 100 15 (18) 15 (18) 15 (18) 15 (18) 15 (18) 15 (18) 130 18 (20) 18 (20) 18 (20) 18 (20) 18 (20) 18 ( (20) 12 (15) 10 (12) 10 (10) 8 (10) 8 (8) 40 18 (20) 15 (18) 12 (15) 10 (12) 8 (10) 8 (10) 70 20 (25) 18 (20) 15 (15) 12 (15) 10 (12) 8 (10) 100 25 (30) 20 (22) 15 (18) 15 (15) 12 (15) 10 (12) 130 30 (35) 25 (27) 18 (22) 15 (18) 15 (18) 12 (15) 160 35 (42) 30 (35) 22 (27) 18 (22) 18 (20) 15 (18) a Administered q12h for five doses.
Byrne et al.
that were associated with a high likelihood of attaining target unbound trough concentrations early in therapy. An important highlight of these simulations was the impact of renal function and serum albumin concentration on teicoplanin total and unbound concentrations. It is important that standard dosing regimens should only be used with caution in patients with haematological malignancy owing to the variation in PK between patients who already have a reduced ability to fight infection due to profound immunosuppression. For all patients we advocate the administration of five loading doses q12h for the first 48 h, stratified according to renal function. For a typical haematological malignancy patient (CL CR 70 mL/min), a loading dose of 12 mg/kg q12h for five doses is needed for a high likelihood of achieving target trough unbound concentrations within 72 h; this is the loading regimen currently recommended for deep-seated infections.
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As shown in Figure 3 , CL CR has a significant impact on total and unbound concentrations, which is in keeping with teicoplanin's renal elimination characteristics. 12 In particular, patients with enhanced renal function may be problematic and very high doses appear necessary to attain target unbound concentrations (Tables 3 and 4 ). The effect of serum albumin concentration on unbound and total teicoplanin concentrations is also highlighted in Figure 3 . As it is unbound drug that is distributed and cleared from the body, the main effect of the increased FF that results from low albumin concentration is a reduction in the concentration of albumin-bound drug in circulation and therefore a reduction in the total drug concentration. This results in reduced target attainment of total teicoplanin concentrations but not unbound concentrations, which has important implications for appropriate dosing.
Patients with low serum albumin concentrations may exhibit suboptimal total concentrations but may have therapeutic unbound concentrations. Therefore a dose increase may not be necessary and may increase the risk of toxicity. In these cases it would be useful to measure unbound concentrations, and there has been a growing contention for therapeutic drug monitoring of unbound teicoplanin concentrations. 8, 9, 19, 26 However, at present, this is not widely feasible. Therefore Table 5 could be used to estimate the unbound teicoplanin concentration from the measured total concentration and the patient's serum albumin concentration. This may provide a more accurate estimate of unbound concentration from total concentration therapeutic drug monitoring data, as opposed to using a fixed FF for all patients, because it accounts for the patient's serum albumin concentration. However, the error associated with the unbound estimates in this table was not small and this must be taken into consideration when using Table 5 . Clearly, direct measurement of unbound teicoplanin concentrations should be considered the preferred approach.
The rich data set employed in this study enabled characterization of a tri-exponential PK model, which is thought to best describe the disposition kinetics of teicoplanin in most cases. 12, 27 Although the binding of teicoplanin to plasma albumin is considered to be linear up to $300 mg/L, 22 the complex (kinetic) binding model used in this study provided a superior fit to the data compared with the simple (linear) binding model. Using FF to predict unbound concentration from total concentration for mechanistic Table 4 . Teicoplanin dosage regimens associated with a probability of (i) !80% and (ii) !90% for achieving trough unbound concentrations of !1.5 mg/L at 72 h and on day 7, and the probability (risk) of attaining trough unbound concentrations !4. Alb, serum albumin concentration; C total , total teicoplanin concentration.
Teicoplanin pharmacokinetics in patients with haematological malignancy JAC purposes suggests that a modification of the FF is automatically responsible for a modification of the unbound concentration, but this is not necessarily the case in the in vivo situation. For most drugs, an increase (or decrease) in the FF corresponds to a decrease (or increase) in total concentration, with no alteration of the unbound concentration, 21 as was found to be the case in the current study. Binding parameters of individual teicoplanin components to human albumin have been previously reported. 5 The K A reported for the major component of the teicoplanin complex (A2-2) was 2.47%10 4 L/mol, which is comparable to the K A calculated in the current study of 2.41%10 4 L/mol, from values for k on and k off derived from the PK analysis. The modelled renal CL for unbound teicoplanin in a patient with normal renal function (CL CR 90 mL/min, 5.4 L/h) was 7.29 L/h (95% CI 4.95, 8.10), which is slightly faster than the glomerular filtration rate. This supports the view that CL of unbound teicoplanin is mainly by glomerular filtration, though tubular secretion could also play a minor role. The lower renal than total CL observed suggests there may be some non-renal CL of teicoplanin, depending on renal function, probably through biliary secretion. 28 Mean V c in the current study of 4.24 L/70 kg (0.06 L/kg) is slightly in excess of the plasma volume, and within the usual expected range for teicoplanin (0.05-0.1 L/kg). 27 Mean K cp (19.15 h
#1
) and K cdp (7.71 h
) were considerably higher than those previously published for K cp (1.53 h
) and K cdp (0.53 h
) in a PK analysis of the same data for total teicoplanin concentrations only. 16 This is to be expected because the current study modelled distribution of unbound drug out of the central compartment, rather than total drug. However, values from the previous study for K pc (0.79 h
) and K dpc (0.03 h
) were similar to the current study because distribution of drug from tissues back to the central compartment does not depend on plasma protein binding. All of these points show that the final three-compartment complex binding model derived in this study is physiologically plausible and adequately describes the disposition of teicoplanin in vivo.
We acknowledge the following limitations. Firstly, this study was conducted in a single centre and a different result may have been obtained if multiple centres had been studied. Secondly, although the sample size was adequate for a PK study, it is small for a clinical study and therefore no conclusions about the clinical implications of these data are possible. 23 Finally, there are no clear targets for unbound or total teicoplanin and therefore the dosing predictions may be different should new targets be established in the future.
In conclusion, to optimize teicoplanin therapy in patients with haematological malignancy individualized dosing is required. The effects of renal function and serum albumin concentrations on unbound and total teicoplanin exposures must be recognized. Our data emphasize the importance of using unbound teicoplanin concentrations to guide dosing. A model-based teicoplanin dosing regimen for patients with haematological malignancy was proposed; however, prospective validation of this is needed.
